EBC-46

Diacylglycerol Mimicry: Why EBC-46 Binds PKC with Exceptional Selectivity

EBC-46 mimics the natural lipid messenger diacylglycerol to activate specific PKC isoforms — a molecular trick that explains its targeted anti-tumour effects.

Marcus Webb

30 Mar 2026 — 3 min read

The Lock and Key of Cellular Signalling

At the heart of EBC-46's anti-tumour activity lies a remarkable feat of molecular mimicry. Tigilanol tiglate, the active compound, structurally resembles diacylglycerol (DAG) — the endogenous lipid second messenger that cells use to activate protein kinase C (PKC) enzymes.^[1] This resemblance is not coincidental. It is the product of millions of years of co-evolutionary pressure between Fontainea picrosperma and the biological systems its chemical defences target.

Understanding this mimicry is essential to understanding why EBC-46 works — and why it works with a selectivity that most synthetic drugs struggle to achieve.

Diacylglycerol and the C1 Domain

In normal cell signalling, receptor activation at the cell membrane triggers phospholipase C to cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). DAG remains membrane-bound and recruits PKC enzymes to the membrane by binding their C1 regulatory domains.^[2]

The C1 domain is a zinc finger motif — a small, highly conserved protein structure that forms a hydrophobic groove perfectly shaped to accommodate DAG's glycerol backbone and acyl chains. When DAG slots into this groove, it triggers a conformational change that releases the pseudosubstrate from the kinase domain, fully activating the enzyme.

How Tigilanol Tiglate Exploits This System

EBC-46 belongs to the diterpene ester family — a class of plant-derived compounds that share structural features with DAG sufficient to bind C1 domains with high affinity. However, unlike DAG, which is rapidly metabolised by diacylglycerol kinase and diacylglycerol lipase, tigilanol tiglate resists enzymatic degradation at the site of injection.^[3]

This metabolic stability means that EBC-46 produces sustained PKC activation at the injection site — a prolonged signal that far exceeds what transient DAG production would achieve. The result is a supraphysiological PKC response localised to the tumour microenvironment.

Isoform Selectivity: Delta and Epsilon

The PKC family comprises at least ten isoforms, grouped into conventional (alpha, beta, gamma), novel (delta, epsilon, eta, theta), and atypical (zeta, iota) subfamilies. Each isoform has distinct tissue distribution, substrate specificity, and biological functions.

Research on EBC-46 indicates preferential activation of the novel PKC isoforms, particularly PKC-delta and PKC-epsilon.^[4] This selectivity has profound implications:

PKC-delta is strongly linked to apoptosis induction, neutrophil recruitment, and vascular permeability — all of which are observed in EBC-46-treated tumours.
PKC-epsilon plays key roles in immune cell activation, particularly in macrophage inflammatory responses and T-cell signalling, consistent with the robust immune infiltration seen after tigilanol tiglate injection.
The atypical PKC isoforms, which lack C1 domains capable of binding DAG-like molecules, are largely unaffected — helping explain why EBC-46 does not trigger widespread, non-specific kinase activation.

From Molecular Mimicry to Tumour Destruction

The downstream consequences of sustained PKC-delta and PKC-epsilon activation are dramatic. Within hours of injection, tigilanol tiglate triggers a coordinated cascade: rapid haemorrhagic necrosis of the tumour vasculature, massive neutrophil and macrophage infiltration, and ultimately complete tumour ablation with wound healing.^[5]^[6]

What makes this cascade therapeutically valuable is its locality. Because tigilanol tiglate is injected directly into the tumour mass and activates PKC isoforms at the injection site, the vascular disruption and immune activation are confined to the tumour and its immediate microenvironment.

Why This Matters for Drug Development

The diacylglycerol mimicry of EBC-46 represents a compelling example of how natural compounds can achieve pharmacological selectivity through evolutionary refinement. Where rational drug design often struggles to produce isoform-selective PKC modulators, Fontainea picrosperma has produced one through natural selection.^[7]

This selectivity profile — potent local activity, minimal systemic effects — is precisely what makes tigilanol tiglate attractive for clinical development as an intratumoral agent for solid tumours.